Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Allergan |
---|---|
Information provided by: | Allergan |
ClinicalTrials.gov Identifier: | NCT00311376 |
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients.
Condition | Intervention | Phase |
---|---|---|
Overactive Bladder |
Biological: botulinum toxin Type A Other: Placebo/Botulinum toxin Type A Other: Placebo/botulinum toxin Type A |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study |
Estimated Enrollment: | 405 |
Study Start Date: | August 2006 |
Estimated Study Completion Date: | September 2010 |
Estimated Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Biological: botulinum toxin Type A
botulinum toxin Type A 200 U (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at > 12 weeks interval
|
2: Experimental |
Biological: botulinum toxin Type A
botulinum toxin Type A 300 U (tx 1) followed by botulinum toxin Type A 300 U (tx 2); injections into detrusor, at > 12 weeks interval
|
3
placebo followed by experimental
|
Other: Placebo/Botulinum toxin Type A
Placebo (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at > 12 weeks interval
|
4
placebo followed by experimental
|
Other: Placebo/botulinum toxin Type A
Placebo (tx 1) followed by botulinum toxin Type A 300 U (tx 2), injections into detrusor, at > 12 weeks interval
|
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Allergan, Inc. | clinicaltrials@allergan.com |
United States, Michigan | |
Recruiting | |
Royal Oak, Michigan, United States |
Study Director: | Medical Director | Allergan |
Responsible Party: | Allergan, Inc. ( Therapeutic Area Head ) |
Study ID Numbers: | 191622-515 |
Study First Received: | April 4, 2006 |
Last Updated: | March 9, 2009 |
ClinicalTrials.gov Identifier: | NCT00311376 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Signs and Symptoms Urinary Bladder, Overactive Botulinum Toxins Cystocele |
Urologic Diseases Urinary Bladder Diseases Peripheral Nervous System Agents Botulinum Toxin Type A |
Urinary Bladder, Overactive Anti-Dyskinesia Agents Urinary Bladder Diseases Physiological Effects of Drugs Neuromuscular Agents Pharmacologic Actions Urological Manifestations |
Signs and Symptoms Botulinum Toxins Urologic Diseases Therapeutic Uses Peripheral Nervous System Agents Botulinum Toxin Type A Central Nervous System Agents |